# Evaluation System for the Efficacy of Immunologic Checkpoint Inhibitors in NSCLC

> **NCT04629027** · — · UNKNOWN · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 80 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Immune checkpoint inhibitor

## Key facts

- **NCT ID:** NCT04629027
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-03
- **Primary completion:** 2023-05-30
- **Final completion:** 2023-05-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2021-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04629027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04629027, "Evaluation System for the Efficacy of Immunologic Checkpoint Inhibitors in NSCLC". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04629027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*